Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as sirolimus use different ways to stop cancer
cells from dividing so they stop growing or die.
PURPOSE: This phase I trial is studying the side effects and best dose of sirolimus in
treating young patients with relapsed or refractory acute leukemia or non-Hodgkin's lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborators:
National Childhood Cancer Foundation The Leukemia and Lymphoma Society